|Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders|
Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) from healthy donors led to high response rates and significant extensions in overall survival (OS) for patients with rituximab-refractory EBV–associated lymphoproliferative ...
OncLive - Sun, 19 Apr 2015 06:10
|T-cell immunotherapy appears effective in post-HSCT lymphoproliferative disorder|
PHILADELPHIA — A new type of T cell-based immunotherapy induced response in a majority of patients with Epstein-Barr virus-associated lymphoproliferative disorder who did not respond to standard treatment, according to study results presented at the ...
Healio - Mon, 20 Apr 2015 05:00
|Human leukocyte antigen polymorphisms and personalized medicine for ...|
It was well known that the development of lymphoproliferative disorders is frequent in RA patients, although the incidence of some other malignancies in RA is relatively lower. A tendency toward a higher frequency of DQB1*06:01 was noted in RA patients ...
Nature.com - Wed, 22 Apr 2015 23:11
|The importance of co-stimulation in the orchestration of T helper cell ...|
Upon their activation, CD4 T cells can differentiate into distinct T helper cell subsets with specialised functions. Different T helper cell subsets produce specific cytokines that mediate beneficial and sometimes detrimental effects, depending on the ...
Nature.com - Tue, 21 Apr 2015 02:44
|Baupost Ups Stake In Atara Biotherapeutics To 19.5 Percent|
Last month, Atara Biotherapeutics obtained a breakthrough therapy designation for its optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) for the treatment of EBV-associated lymphoproliferative disease (EBV-LPD), a serious ...
ValueWalk - Tue, 14 Apr 2015 04:48
|Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and ...|
... that have on-site access to equipment and personnel trained to manage anaphylaxis and serious infusion reactions. Lemtrada may be associated with an increased risk of malignancy including thyroid cancer melanoma and lymphoproliferative disorders.
PharmiWeb.com (press release) - Mon, 13 Apr 2015 08:00
|Product Profile: Lemtrada (alemtuzumab)|
Lemtrada carries a black box warning for the potential to cause serious autoimmune conditions, possibly life-threatening infusion reactions, and an increased risk of malignancy (eg, thyroid cancer, melanoma, and lymphoproliferative disorders). As a ...
HCPLive - Thu, 09 Apr 2015 10:48
|Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B ...|
The FDA's Orphan Drug Designation program grants orphan status to drugs and biologics that are intended for use in rare diseases/ or disorders, defined as those that affect fewer than 200,000 people in the U.S. or that affect more than 200,000 people ...
MarketWatch - Mon, 06 Apr 2015 03:52